CHM.AX Chimeric Therapeutics Limited
Company Analysis
Latest News
Chimeric's 60% Response Rate in Blood Cancer Patients Is Eye-Catching — But Can a $3 Million Company Turn It Into a Real Business?
Shares in Chimeric Therapeutics (CHM.AX) continue to drift higher at $0.07, up roughly 8% this week, as investors digest a two-month-old clinical milestone...
🟢 CHM.AX is trading 8% up today as trial optimism fuels ongoing rebound
CHM.AX is trading up 8% at $0.07, continuing its recovery as investors remain optimistic following strong clinical trial data. • Sentiment remains supported...
🔴 CHM.AX is trading 7% down today amid broader weakness in micro-cap biotech sentiment
CHM.AX is trading approximately 7% down at $0.06 today, extending its recent volatility despite a lack of new company-specific catalysts. • No fresh...
🔴 Chimeric Therapeutics Limited is trading 7% down today amid low-liquidity trading
Chimeric Therapeutics Limited is trading 7% down today at $0.07 following several days of incremental declines and typical micro-cap biotech volatility. •...
🔴 Chimeric Therapeutics Limited is trading 7% down today with no clear catalyst
Chimeric Therapeutics Limited is trading at $0.07, down 7% today, following several days of incremental declines and heightened volatility typical for this...
🔴 Chimeric Therapeutics Limited is trading 5.3% down today on light, news-thin trading
Chimeric Therapeutics Limited is trading 5.3% down at $0.071 following a session of light, news-thin trading with no fresh company catalysts. * Trading volume...
🔴 Chimeric Therapeutics Limited is trading 4% down today on light, news-thin trading
Chimeric Therapeutics Limited is trading 4% down at $0.07 on light, news-thin trading, extending recent volatility in this micro-cap biotech name. • The move...